Testosterone replacement therapy for bone loss prevention in HIV-infected males.
OBJECTIVE
To review the use of testosterone for the prevention of bone loss in men with HIV infection.


METHODS
A MEDLINE search (1966-May 2002) on the use of testosterone in osteoporosis/HIV infection was performed. A reference bibliography search was also completed.


RESULTS
Osteopenia/osteoporosis is reported in HIV-infected men due to a myriad of factors. Sex hormone deficiency is a frequent endocrine abnormality in this population.


CONCLUSIONS
In HIV-negative men, testosterone may be beneficial for preventing bone loss and hastening the resolution of fractures. Testosterone's role in preventing bone loss in HIV-infected men remains to be defined.
Clay
Patrick G
PG
Division of Pharmacy Practice, School of Pharmacy, University of Missouri at Kansas City, Kansas City, MO 64108, USA. claypg@umkc.edu
Lam
Amy I
AI
D001851:Bone Diseases, Metabolic / Q000150:complications* / Q000188:drug therapy / Q000517:prevention & control*; D006678:HIV / Q000302:isolation & purification; D015658:HIV Infections / Q000150:complications* / Q000821:virology; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D008297:Male; D013739:Testosterone / Q000008:administration & dosage / Q000627:therapeutic use*
D013739:Testosterone